|Budesonide||Inhaled corticosteroid (ICS)|
|Salmeterol||Long-acting beta agonist (LABA)|
|Other names||Budesonide/salmeterol xinafoate|
|Side effects||Throat inflammation, headache, voice changes, worsened asthma|
Budesonide/salmeterol (B/S), sold under the brand name Labazenit, is a combination medication used in the long-term treatment of asthma. It main be used when an inhaled steroid alone is insufficient. It is used by breathing the medication into the lungs.
Side effects may include throat inflammation, headache, voice changes, and worsened asthma. Serious side effects are uncommon. It contains budesonide, an inhaled corticosteroid (ICS) and salmeterol, a long-acting beta agonist (LABA).
It was denied approval in Europe in 2013. It had not been approved for medical use in any country as of 2015. It is on the World Health Organization's List of Essential Medicines as an alternative to budesonide/formoterol.
- Popov, TA; De Niet, S; Vanderbist, F (February 2016). "Budesonide/salmeterol in fixed-dose combination for the treatment of asthma". Expert review of respiratory medicine. 10 (2): 113–25. doi:10.1586/17476348.2016.1133302. PMID 26677916.
- "Labazenit". European Medicines Agency. 17 September 2018. Archived from the original on 3 June 2023. Retrieved 23 August 2023.
- World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.